How Is The Macular Degeneration Treatment Market Expected To Grow At 11.1% CAGR Over 2025–2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Macular Degeneration Treatment Market Be Worth By 2029?
The market size for macular degeneration treatment has seen significant growth in recent times. The market is anticipated to expand from $11.05 billion in 2024 to $12.38 billion in 2025, witnessing a compound annual growth rate (CAGR) of 12.0%. Contributory factors for this growth during the historical period include an increasing elderly population, changes in lifestyle, limited options for treatment, enhanced awareness, and developments in healthcare infrastructure.
Rapid advancement is predicted in the near future for the macular degeneration treatment market, with a size expected to reach $18.87 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.1%. The anticipated expansion during the forecast period can be credited to breakthroughs in research, escalated healthcare spending, rising occurrences, tailored medical treatments, and worldwide campaigns for eye health. Noteworthy patterns expected during this period incorporate emphasis on neuroprotection and regeneration therapies, wider use of telemedicine and remote monitoring, personalized medicine strategies, exploration of stem cell treatments, and initiatives centered on patient awareness and education.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp
What External And Internal Drivers Are Influencing The Macular Degeneration Treatment Market?
The escalating incidence of retinal disorders is predicted to drive the expansion of the macular degeneration treatment market. Such disorders attack the essential tissue, compromising the manner in which individuals interpret visual data, causing blurry or non-existent vision. For example, data from the American Academy of Ophthalmology predicts that by 2050, roughly 7.32 million inhabitants of the United States will be affected by primary open-angle glaucoma. This is a blanket term encompassing various eye disorders, predominantly affecting individuals aged 70 to 79 years (32%), females (50%), and Hispanics (50%), with Hispanic males making up the majority. Hence, the rising incidence of retinal disorders is accelerating the expansion of the macular degeneration treatment market.
What Segmentation Insights Are Provided In The Macular Degeneration Treatment Market Research?
The macular degeneration treatmentmarket covered in this report is segmented –
1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
3) By Route of Administration: Oral; Injectable; Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
Subsegments:
1) By Early-Stage AMD: Nutritional Supplements; Lifestyle Modification Treatments
2) By Intermediate AMD: Anti-VEGF Injections; Photodynamic Therapy
3) By Late-Stage AMD: Surgical Treatments; Advanced Anti-VEGF Therapies; Gene Therapy Options
Which Market Trends Are Expected To Define The Future Of The Macular Degeneration Treatment Market?
Key players in the macular degeneration treatment market are investing in the development of biosimilars for age-related macular degeneration (AMD) treatment, aiming to improve access to effective therapies. The term ‘biosimilars’ refers to biological medications that are almost indistinguishable from an already authorized reference product, featuring no substantial variations in safety, purity or efficacy. For example, in May 2024, Indian firm Biocon Biologics Ltd and South Korean corporation Samsung Bioepis Co. Ltd, obtained FDA approval for two novel biosimilars, Yesafili and Opuviz. These biosimilars act by inhibiting the vascular endothelial growth factor (VEGF), the substance responsible for irregular blood vessel formation in the eyes. This mechanism of action aids in preventing vision loss in diseases like AMD and diabetic retinopathy. The FDA’s green light was based on comparative studies that demonstrated the similar efficacy and safety of Yesafili and Opuviz to Eylea, supported by thorough evaluations of the biosimilars’ pharmacokinetics and immunogenicity.
Who Are The Leading Companies Driving The Macular Degeneration Treatment Market?
Major companies operating in the macular degeneration treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Panoptica, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Santen Pharmaceuticals, Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Applied Genetic Technologies Corp (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Macular Degeneration Treatment Market?
North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp
Browse Through More Reports Similar to the Global Macular Degeneration Treatment Market 2025, By The Business Research Company
Gastrointestinal Bleeding Treatment Devices Global Market Report 2025
Gastrointestinal Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report
Medical Equipment Maintenance Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/medical-equipment-maintenance-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
